Department of Endocrine, Digestive and Oncological Surgery, Robert-Debré University Hospital, Reims, France.
Faculty of Medicine, UR 3797 Ageing, Frailty (VieFra), University of Reims Champagne-Ardenne, Reims, France.
J Neuroendocrinol. 2022 Jun;34(6):e13117. doi: 10.1111/jne.13117. Epub 2022 Apr 18.
Complete surgical resection is the only hope to cure small intestine neuroendocrine neoplasms (SiNENs). However, inadequate lymphadenectomy or entire small bowel palpation for multiple primary tumours renders at least 20% of resections suboptimal. This study was undertaken to investigate reintervention outcomes after initial suboptimal resections (ISORs), and agreement between residual tumour identification on interval imaging and during reintervention. This retrospective, multicentre study included all patients undergoing reintervention within 18 months post ISOR. Disease-free survival (DFS) was defined as the time from reintervention resection date to recurrence or any-cause of death. The kappa coefficient assessed agreement rates between suspected residual tumour on interval imaging and its presence at reintervention. A total of 21 patients underwent reintervention for nonmetastatic SiNENs (median follow-up 2.3 [IQR 0.6-3.75] years). Residual tumour, suspected in 17/21 (81%) patients based on interval imaging, was found in 20/21 (95%) during reintervention. Interval imaging-intraoperative detection agreement was fair for residual primary tumours (kappa = 0.28, 95% CI: 0.05-0.62; p = .09) and residual lymph node metastases (kappa = 0.17, 95% CI: 0.28-0.62; p = .45). Reintervention achieved complete tumour clearance in 16/21 (76%) patients, among whom 5/16 (31%) developed liver metastases during follow-up. Median DFS was 70.6 months (IQR 39.7-not reached). Reintervention post-ISOR can obtain tumour clearance and prolonged remission. It should be systematically discussed after suspected ISOR, even when postoperative imaging does not find any residual tumour. To maximize detection of potentially resectable residual disease, imaging modalities after "curative" surgery should be redefined.
完整的手术切除是治愈小肠神经内分泌肿瘤(SiNENs)的唯一希望。然而,由于淋巴结清扫不足或对多个原发肿瘤进行全小肠触诊,至少有 20%的切除手术并不理想。本研究旨在探讨初始次优切除(ISOR)后的再次干预结果,以及间隔影像学检查和再次干预时对残留肿瘤识别的一致性。这是一项回顾性、多中心研究,纳入了所有在 ISOR 后 18 个月内进行再次干预的患者。无病生存(DFS)定义为从再次干预切除日期到复发或任何原因死亡的时间。kappa 系数评估了间隔影像学上可疑残留肿瘤与再次干预时存在的肿瘤之间的一致性。共有 21 例非转移性 SiNENs 患者接受了再次干预(中位随访 2.3 [IQR 0.6-3.75] 年)。根据间隔影像学检查,在 21 例患者中有 17 例(81%)怀疑存在残留肿瘤,在 21 例患者中有 20 例(95%)在再次干预时发现了残留肿瘤。对于残留的原发性肿瘤(kappa=0.28,95%CI:0.05-0.62;p=0.09)和残留淋巴结转移(kappa=0.17,95%CI:0.28-0.62;p=0.45),间隔影像学-术中检测的一致性为中等。21 例患者中有 16 例(76%)再次干预后肿瘤完全清除,其中 5 例(31%)在随访期间发生肝转移。中位 DFS 为 70.6 个月(IQR 39.7-未达到)。ISOR 后再次干预可获得肿瘤清除和延长缓解期。即使术后影像学检查未发现任何残留肿瘤,也应在术后系统讨论再次干预的可能性。为了最大限度地发现潜在可切除的残留疾病,应重新定义“治愈性”手术后的影像学检查方式。